We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
+13.09%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$199M
AUM Growth
-$10.2M
(-4.8%)
Cap. Flow
-$25.1M
Cap. Flow
% of AUM
-12.57%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
6
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$5.01M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$631K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UAM
Universal American Corp
UAM
|
+$21.6M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$3.7M |
| 3 |
AIMT
Aimmune Therapeutics
AIMT
|
+$2.7M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$1.58M |
| 5 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$608K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
| $78.4M | 39.37% |
3,835,830
-132,070
| -3% | -$2.7M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $59.6M | 29.91% |
1,574,749
-97,965
| -6% | -$3.7M |
|
|
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
| $20.7M | 10.39% |
995,396
+192,672
| +24% | +$5.01M |
|
|
EPZM
4
DELISTED
Epizyme, Inc
EPZM
| $18.5M | 9.27% |
1,526,637
-16,481
| -1% | -$172K |
|
|
NSTG
5
DELISTED
NanoString Technologies, Inc.
NSTG
| $15.1M | 7.6% |
679,033
-73,824
| -10% | -$1.58M |
|
|
NVET
6
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
| $3.34M | 1.68% |
894,695
-5,460
| -0.6% | -$22.5K |
|
7
Larimar Therapeutics
LRMR
$416M
| $2.11M | 1.06% |
55,315
-8,022
| -13% | -$325K |
|
|
OREX
8
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $944K | 0.47% |
542,755
| – | – |
|
|
XLRN
9
DELISTED
Acceleron Pharma
XLRN
| $508K | 0.25% |
+19,910
| New | +$631K |
|
|
UAM
10
DELISTED
Universal American Corp
UAM
| – | – |
-2,820,791
| Closed | -$21.6M |
|
|
BDSI
11
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| – | – |
-225,281
| Closed | -$608K |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q4 2016 Portfolio in Review
As of Q4 2016, Foresite Capital Management II held 11 positions worth $199M, down 4.8% from $209M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II withdrew a net $25.1M in Q4 2016, closing 2 positions and reducing 6 holdings. Its most notable exit was Universal American Corp, an estimated $21.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 41% a quarter earlier.
Against the trend, Foresite Capital Management II opened a new position in Acceleron Pharma worth $508K.
- Foresite Capital Management II's largest Q4 2016 buy was Acceleron Pharma: 19,910 shares worth $508K.
- Foresite Capital Management II added most to Alder Biopharmaceuticals in Q4 2016, an estimated $5.01M increase.
- Foresite Capital Management II's biggest Q4 2016 reduction was Aerie Pharmaceuticals, cutting an estimated $3.7M.
- Foresite Capital Management II fully exited Universal American Corp in Q4 2016, selling an estimated $21.6M.
- Foresite Capital Management II's ten largest holdings make up 100% of its $199M portfolio in Q4 2016.
- Foresite Capital Management II opened 1 new position and closed 2 in Q4 2016.
- Foresite Capital Management II's portfolio value fell 4.8% quarter-over-quarter to $199M.
Based on Foresite Capital Management II's 13F filing for Q4 2016, filed 10 Feb 2017.